Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats

Cancer Letters

Volumn 101, Issue 1, 1996, Pages 21-24

  Pollard, Morris ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Anti angiogenesis; Metastasis; Prostate cancer; Thalidomide

Indexed keywords

THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER GRAFT; CANCER TRANSPLANTATION; CONTROLLED STUDY; IMMUNOSUPPRESSIVE TREATMENT; LUNG METASTASIS; LYMPH VESSEL; MALE; METASTASIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RAT; TUMOR CELL; TUMOR VOLUME;

ANIMALIA; ORYCTOLAGUS CUNICULUS; ZEA MAYS;

EID: 0030068591     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3835(95)04105-2     Document Type: Article

References (17)

1. McBride, W.G. (1961) Thalidomide and congenital abnormalities. Lancet, ii, 1958.
2. Lenz, W. (1962) Thalidomide and congenital abnormalities. Lancet, i, 45.
3. Field, E.O., Gibbs, J.E., Tucker, D.F. and Hellmann, K. (1966) Effect of thalidomide on the graft vs host reaction. Nature, 21, 1308-1309.
4. Vogelsang, G.B., Hess, A.D, Friedman, K.J. and Santos, G.W. (1989) Therapy of chronic graft vs host disease in a rat model. Blood, 74, 507-511.
5. Sheskin, J. (1965) Thalidomide in treatment of lepra reactions. Clin. Pharmacol. Then., 6, 303-306.
6. Grosshans, E. and Illy, G. (1984) Thalidomide therapy for inflammatory dermatoses. Int. J. Dermatol., 23, 598-602.
7. D'Amato, R.J., Longhnan, M.S., Flynn, E. and Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA, 91, 4082-4085.
8. Pollard, M, Luckert, P.H. and Snyder, D. (1989) Prevention of prostate cancer and liver tumors in L-W rats by moderate dietary restriction. Cancer, 64, 686-690.
9. Pollard, M. and Luckert, P.H. (1975) Transplantable metastasizing adenocarcinomas in rats. J. Natl. Cancer Inst., 54, 643-649.
10. Pollard, M and Luckert, P.H. (1979) Patterns of spontaneous metastasis manifested by three rat prostate adenocarcinomas. J. Surg. Oncol., 12, 371-377.
11. Pollard, M. (1992) The Lobund-Wistar rat model. J. Cell. Biochem., Suppl. 16H, 84-88.
12. Pollard, M. and Luckert, P.H. (1990) In vivo model systems for assessing an anti-cancer drug: responses of autochthonous and transplanted prostate tumors to cyclophosphamide. Anticancer Res., 20, 33-36.
13. Pollard, M., Burleson, G.R. and Luckert, P.H. (1981) Interference with in vivo growth and metastasis of prostate adenocarcinoma (PA-III) by ICRF-159. The Prostate, 2, 1-10.
14. Neubauer, B.L., Bemis, K.G., Best, K.L., Goode, R.L., Hoover, D.M., Smith, G.F., Tanzer, R.L. and Merriman, R.L. (1986) Inhibitory effect of warfarin on the metastasis of the PA III prostatic adenocarcinoma in the rat. J. Urol., 135, 163-166.
15. Pollard, M. and Luckert, P.H. (1991) The inhibitory effect of 4-hydroxyphenyl retinamide (4 HPR) on metastasis of prostate adenocarcinoma-III cells in Lobund-Wistar rats. Cancer Lett., 59, 159-164.
16. Pollard, M., Burleson, G.R. and Luckert, P.H. (1977) Factors that modify the rate and extent of spontaneous metastases of prostate tumors in rats. In: Cancer Invasion and Metastasis: Biologic Mechanisms and Therapy, pp. 357-366. Editor: S.B. Day. Raven Press, New York.
17. Pollard, M. and Luckert, P.H. (1993) The anti-metastatic effect of intravenously-inoculated BCG on prostate tumor cells. Anticancer Res., 13, 705-708.